Evaluation of Anterior Middle Brain Structures With Cerebrovascular Flow

Status Active, not recruiting

Clinical Trial Summary

The study will be conducted to examine the effects of abnormal growth pattern and cerebrovascular blood flow measurements on fetal frontal lobe development with the advancing ultrasound technology. Antenatal assessment of frontal lobe development will enable clinicians to predict neurodevelopmental problems that may develop postnatally. In addition, this study will examine the effects of FGR on frontal lobe development.

Clinical Trial Description

Fetal growth restriction (FGR) affects up to 10% of all pregnancies. The International Society of Ultrasound in Obstetrics & Gynecology (ISUOG) adopts the Delphi consensus criteria for the definition of FGR. These criteria include estimated fetal weight (EFW) or abdominal circumference (AC) < 3rd percentile or EFW or AC < 10th percentile with abnormal Doppler findings or decreased growth percentiles. FGR is a cause of perinatal morbidity and mortality. These perinatal outcomes include cardiovascular, endocrine and neurodevelopmental disorders. Fetal growth restriction, which is associated with lower neurobehavioral test scores, is associated with significant postnatal costs for both the health care system and families. Previous literature has shown that three-dimensional ultrasonography of intracranial structures reveals significant differences between fetuses with FGR and gestational age-appropriate (AGA) fetuses. However, the limited use of three-dimensional ultrasonography has hindered clinical applications. The frontal Anterior-Posterior Diameter (FAPD)/Occipital-Frontal Diameter (OFD) ratio has recently been used to assess frontal lobe development in fetuses with congenital heart disease. The FAPD is obtained by measuring from the inner line of the frontal bone along the fetal brain midline to the posterior edge of the CSP. This measurement refers to the frontal lobe of the fetal cerebrum. This study was designed to investigate the FAPD/ OFD ratio and frontal lobe development in fetuses with FGR and to evaluate cerebrovascular flow and anterior midbrain structures in FGR fetuses. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT06215690
Study type	Observational
Source	Ankara Etlik City Hospital
Contact
Status	Active, not recruiting
Phase
Start date	March 31, 2023
Completion date	March 15, 2024

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT05899101` - The Impact of Opioid and Cannabis Exposure on Fetal Growth
Completed	`NCT04502823` - Management of Fetal Growth Restriction at Term: Angiogenic Factors Versus Feto-placental Doppler	N/A
Not yet recruiting	`NCT03625518` - Mode of Induction in Fetal Growth Restriction and Its Affects on Fetal and Maternal Outcomes	Early Phase 1
Completed	`NCT05176041` - SLE Therapy Changes in Pregnancy and Relation to Pregnancy Outcome
Completed	`NCT02379728` - Ghana PrenaBelt Trial: A Positional Therapy Device to Reduce Still-Birth	N/A
Completed	`NCT01695070` - Melatonin to Prevent Brain Injury in Unborn Growth Restricted Babies	Phase 4
Completed	`NCT01352234` - Comparison of Doses of Acetylsalicylic Acid in Women With Previous History of Preeclampsia	Phase 4
Not yet recruiting	`NCT05284474` - Management of Early-onset Fetal Growth Restriction: Angiogenic Factors Versus Feto-placental Doppler	N/A
Completed	`NCT04289350` - Day to Day Variation in Fetal Heart Rate Variability
Recruiting	`NCT03662178` - Investigating the Structured Use of Ultrasound Scanning for Fetal Growth
Recruiting	`NCT05023161` - Non-invasive Placental Chromosome Exploration of Intrauterine Growth Restriction
Completed	`NCT02590536` - A Trial Evaluating the Role of Sildenafil in the Treatment of Fetal Growth Restriction	Phase 3
Not yet recruiting	`NCT05029778` - Arginine + Citrulline as a Supplement for Weight Gain in Fetus With a Decrease in Their Growth Curve	Phase 4
Recruiting	`NCT05576207` - BEP Supplementation Research in Bangladesh (JiVitA-BEP-IR)	N/A
Active, not recruiting	`NCT05160649` - Effect of Covid 19 Infection on Fetomaternal Outcome
Completed	`NCT02280031` - Effect of Low Dose Aspirin on Birthweight in Twins: The GAP Trial.	Phase 2
Recruiting	`NCT04389099` - MRI Angiography of Physiological and Pathological Pregnancy Placentas Ex-vivo
Recruiting	`NCT06039319` - Acute Effects of Maternal Exercise and the Growth Restricted Pregnancy
Recruiting	`NCT05651347` - Antenatal Melatonin Supplementation for Neuroprotection in Fetal Growth Restriction	Phase 3
Recruiting	`NCT02336243` - A Randomized Trial of Docosahexaenoic Acid Supplementation During Pregnancy to Prevent Deep Placentation Disorders	Phase 3

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Evaluation of Anterior Middle Brain Structures With Cerebrovascular Flow in Fetuses With Fetal Growth Restriction

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms